This gene is an indirect target of the BCR‐ABL chimeric protein (Hjort et al., 2016), and a candidate oncogene because of its involvement in CML cell growth and survival, particularly via the Wnt/β‐catenin pathway (Huang et al., 2017; Zhou et al., 2014). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.